A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel

Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin’s lymphoma, and glioblastoma....

Descripción completa

Detalles Bibliográficos
Autores principales: Piawah, Sorbarikor, Hyland, Colby, Umetsu, Sarah E., Esserman, Laura J., Rugo, Hope S., Chien, A. Jo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570645/
https://www.ncbi.nlm.nih.gov/pubmed/31240240
http://dx.doi.org/10.1038/s41523-019-0112-z
_version_ 1783427269897748480
author Piawah, Sorbarikor
Hyland, Colby
Umetsu, Sarah E.
Esserman, Laura J.
Rugo, Hope S.
Chien, A. Jo
author_facet Piawah, Sorbarikor
Hyland, Colby
Umetsu, Sarah E.
Esserman, Laura J.
Rugo, Hope S.
Chien, A. Jo
author_sort Piawah, Sorbarikor
collection PubMed
description Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin’s lymphoma, and glioblastoma. Here, we report a case of severe drug-induced liver injury requiring liver transplantation due to vanishing bile duct syndrome (VBDS) after exposure to pexidartinib in the I-SPY 2 Trial, a phase 2 multicenter randomized neoadjuvant chemotherapy trial in patients with Stage II–III breast cancer. We also review the current literature on this rare, idiosyncratic, and potentially life-threatening entity.
format Online
Article
Text
id pubmed-6570645
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-65706452019-06-25 A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel Piawah, Sorbarikor Hyland, Colby Umetsu, Sarah E. Esserman, Laura J. Rugo, Hope S. Chien, A. Jo NPJ Breast Cancer Case Report Pexidartinib (PLX3397) is a small molecule tyrosine kinase and colony-stimulating factor-1 inhibitor with FDA breakthrough therapy designation for tenosynovial giant-cell tumor, and currently under study in several other tumor types, including breast cancer, non-Hodgkin’s lymphoma, and glioblastoma. Here, we report a case of severe drug-induced liver injury requiring liver transplantation due to vanishing bile duct syndrome (VBDS) after exposure to pexidartinib in the I-SPY 2 Trial, a phase 2 multicenter randomized neoadjuvant chemotherapy trial in patients with Stage II–III breast cancer. We also review the current literature on this rare, idiosyncratic, and potentially life-threatening entity. Nature Publishing Group UK 2019-06-14 /pmc/articles/PMC6570645/ /pubmed/31240240 http://dx.doi.org/10.1038/s41523-019-0112-z Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Case Report
Piawah, Sorbarikor
Hyland, Colby
Umetsu, Sarah E.
Esserman, Laura J.
Rugo, Hope S.
Chien, A. Jo
A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
title A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
title_full A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
title_fullStr A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
title_full_unstemmed A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
title_short A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
title_sort case report of vanishing bile duct syndrome after exposure to pexidartinib (plx3397) and paclitaxel
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570645/
https://www.ncbi.nlm.nih.gov/pubmed/31240240
http://dx.doi.org/10.1038/s41523-019-0112-z
work_keys_str_mv AT piawahsorbarikor acasereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT hylandcolby acasereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT umetsusarahe acasereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT essermanlauraj acasereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT rugohopes acasereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT chienajo acasereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT piawahsorbarikor casereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT hylandcolby casereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT umetsusarahe casereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT essermanlauraj casereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT rugohopes casereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel
AT chienajo casereportofvanishingbileductsyndromeafterexposuretopexidartinibplx3397andpaclitaxel

Ejemplares similares